icrucumab
mAbexperimental
Icrucumab (IMC-18F1) is a human monoclonal antibody designed for the treatment of solid tumors. — Wikipedia
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2006 (NCT00782002)
Timeline
Indications
Mechanism of action
FLT1 antagonist
Human monoclonal antibody against vascular endothelial growth factor receptor-1 (VEGFR-1), potently inhibits ligand-dependent phosphorylation of VEGFR-1 and downstream signaling,
FLT1 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaIcrucumab ↗
- ChEMBLCHEMBL1743030 ↗
Also known as
- icrucumab
- imc-18f1
- imc-18f1
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01282463 | Phase 2 | Apr 1, 2011 | Eli Lilly |
| NCT01234402 | Phase 2 | Mar 1, 2011 | Eli Lilly |
| NCT01111604 | Phase 2 | Aug 1, 2010 | Eli Lilly |
| NCT00782002 | Phase 1 | Jul 1, 2006 | Imclone |
Showing 4 of 4 trials
Page 1 / 1